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Abstract 
Objectives 
To investigate the potential clinical benefit of an intra-aortic balloon pump (IABP) in patients supported with 
venoarterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to heart transplantation (HT). 
Methods 
We studied 169 patients who were listed for urgent HT under VA-ECMO support at 16 Spanish institutions from 
2010 to 2015. The clinical outcomes of patients under simultaneous IABP support (n = 73) were compared to a 
control group of patients without IABP support (n = 96). 
Results 
There were no statistically significant differences between the IABP and control groups with regard to the 
cumulative rates of transplantation (71.2% vs 81.2%, P = 0.17), death during VA-ECMO support (20.6% vs 14.6%, 
P = 0.31), transition to a different mechanical circulatory support device (5.5% vs 5.2%, P = 0.94) or weaning from 
VA-ECMO support due to recovery (2.7% vs 0%, P = 0.10). There was a higher incidence of bleeding events in the 
IABP group (45.2% vs 25%, P = 0.006; adjusted odds ratio 2.18, 95% confidence interval 1.02–4.67). In-hospital 
postoperative mortality after HT was 34.6% in the IABP group and 32.5% in the control group (P = 0.80). One-year 
survival after listing for urgent HT was 53.3% in the IABP group and 52.2% in the control group (log rank P = 0.75). 
Multivariate adjustment for potential confounders did not change this result (adjusted hazard ratio 0.94, 95% 
confidence interval 0.56–1.58). 
Conclusions 
In our study, simultaneous IABP therapy in transplant candidates under VA-ECMO support did not significantly 
reduce morbidity or mortality. 
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Heart transplantation (HT) is the therapy of choice for patients with refractory heart failure [1]. Given 
the scarcity of donors, an increasing number of candidates undergo HT under a high-urgency indication 
[2], which frequently requires preoperative mechanical circulatory support [3]. 
 
Given the peculiarities of the Spanish organ-sharing network, venoarterial extracorporeal membrane 
oxygenation (VA-ECMO) is commonly used as a direct bridge to high-urgency HT for critically ill 
candidates [2, 3]. The main advantage of this device is its easy implantation, which enables the immediate 
initiation of advanced circulatory and respiratory support through percutaneous access. Therefore, VA-
ECMO is especially useful for the initial management of patients in cardiogenic shock or cardiac arrest. 
 
Left ventricular distension and pulmonary congestion due to increased afterload are frequent 
complications in patients supported with VA-ECMO [4]. It has been suggested that the ancillary use of an 
intra-aortic balloon pump (IABP) in these individuals might lead to improved unloading of the left 
ventricle, which could help prevent hydrostatic pulmonary oedema [5]. However, previous studies have 
reported controversial results regarding the impact of this strategy in terms of survival [6–9]. 
 
The aim of our investigation was to determine the efficacy and safety of the ancillary use of an IABP 
in patients supported with VA-ECMO, with a primary intention of the bridge to transplantation. Previous 
multicentre studies reporting the results of VA-ECMO in this situation did not address this specific 
question [10, 11]. 
Methods 
Study description 
The ASIS-TC study [12], was a retrospective multicentre registry that included all consecutive 
patients who were treated with temporary mechanical circulatory support devices, and subsequently listed 
for first, single-organ, high-urgency HT in Spain between 2010 and 2015. All of the 16 adult HT centres 
of Spain were involved in the registry. The study protocol was approved by the Committee for Ethics in 
Clinical Research of the Autonomous Community of Galicia, Spain, and ratified by the institutional 
review boards of all participating institutions. 
 
In this article, we describe the clinical outcomes of patients in the ASIS-TC registry who received 
simultaneous support with VA-ECMO and IABP, as compared to patients who were supported solely 
with VA-ECMO. 
Outcomes 
The primary outcome of this study was 1-year survival after listing for high-urgency HT. Secondary 
outcomes included the cumulative incidence of death from any cause, HT, weaning from VA-ECMO due 
to clinical improvement (‘recovery’) and transition to a different mechanical device during the in-hospital 
period following listing, and the cumulative incidence of adverse clinical events during VA-ECMO 
support. Device dysfunction, bleeding events, stroke and device dysfunction were considered major 
adverse clinical events during VA-ECMO support. Complete follow-up was available for all patients. 
 
In patients who underwent high-urgency HT, while on VA-ECMO support, we also analysed the 
cumulative incidence of postoperative death and postoperative adverse clinical events until hospital 
discharge. For this analysis, patients were considered to have been treated simultaneously with VA-
ECMO and IABP if both devices were in place and functioning at the time of listing, even if the IABP 
was removed during the waiting period before transplantation. 
 
Specific definitions of all study outcomes are detailed in the Supplementary Material. 
 
Statistical analysis 
In this article, quantitative variables are expressed as mean (standard deviation, SD), and categorical 
variables are expressed as proportions. For intergroup comparisons, the Student’s t-test and the χ2 test 
were used as required. 
 
The cumulative probability of death and adverse clinical events was represented graphically by means 
of Kaplan–Meier curves, which were statistically compared using the log-rank test. 
 
The multivariable Cox’s regression analysis was performed to control the effect of confusion bias on 
the statistical association between IABP use and 1-year survival. In a first step, we calculated the 
univariate hazard ratios for the outcome of interest for all baseline clinical variables listed in Table 1 that 
showed a statistically significant or near-significant (P < 0.010) different distribution between the IABP 
and control groups. Then, those variables that also showed a statistically significant univariate association 
with 1-year survival entered the final multivariable model, to calculate the adjusted hazard ratio for 1-year 
survival for IABP support versus control. Following a similar procedure, multivariable logistic regression 
was used to assess confusion bias regarding the risk of bleeding events. 
 




Between January 2010 and December 2015, 169 patients supported with VA-ECMO were listed for 
high-urgency HT in 16 Spanish institutions. Seventy-three (43%) patients were simultaneously supported 
with an IABP at the time of listing (IABP group). In 68 of them, the IABP had been inserted before VA-
ECMO implantation and was maintained afterwards. 
 
The remaining 96 (57%) patients were supported solely with VA-ECMO at the time of listing for 
high-urgency HT (control group). Among them, 15 (16%) had been supported with IABP before VA-
ECMO, but the first device was removed after insertion of the oxygenator. 
 
Patients supported simultaneously with VA-ECMO and IABP presented with shock related to a 
myocardial infarction more frequently than patients in the control group. In addition, a higher proportion 
of patients in the IABP group were treated with mechanical ventilation and vasoactive drugs (Table 1). 
 
The proportion of patients who received double antiplatelet therapy was higher in the IABP group 
than in the control group; however, the mean values of haemoglobin concentration and international 
normalized ratio were significantly higher in the latter. Only 2 patients in each group had an apical vent 
for left ventricular unloading. No other therapies for left ventricular unloading, such as left ventricular 
assist device implantation or atrial septostomy, were used at baseline in the studied patients 
Outcomes of venoarterial extracorporeal membrane oxygenation support 
Twenty-nine (17.2%) patients died and 126 (76.3%) were transplanted, while under VA-ECMO 
support. Nine (5.3%) patients transitioned from VA-ECMO to a different mechanical device: 6 patients to 
Centrimag®, 2 patients to BerlinHeart Excor® and 1 patient to Maquet Rotaflow®. Only 2 (1.2%) 
patients had the VA-ECMO explanted due to recovery. 
 
The mean (SD) duration of VA-ECMO support was 10 (6.3) days in the IABP group and 9.5 (9.2) 
days in the control group (P = 0.68). No statistically significant differences between the IABP and control 
groups were observed with regard to the cumulative incidence of death from any cause (20.6% vs 14.6%, 
P = 0.31), transplantation (71.2% vs 80.2%, P = 0.17), transition to another mechanical device (5.5% vs 
5.2%, P = 0.91) or weaning from VA-ECMO due to recovery (2.7% vs 0%, P = 0.19) during this support 
period (Fig. 1). 
Table 1: Baseline clinical characteristics of patients in both study groups 
     VA-ECMO + IABP (n = 73) VA-ECMO alone (n = 96) P-value 
 
Age (years), mean (SD)    49.4 (12.7)   50.9 (13.3)   0.46  
Women, n (%)     18 (24.7)    23 (24)    0.92  
Body mass index (kg/m2), mean (SD)   25.3 (5.1)    26 (4.2)    0.39  
Configuration of VA-ECMO        
 Arterial cannulation site            0.049  
  Peripheral, femoral artery (%)   67 (91.8)    76 (79.2)    
  Peripheral, subclavian artery (%)   3 (4.1)    15 (15.6)    
  Central (%)     3 (4.1)    5 (5.2)    
 Left ventricular apical venting, n (%)   2 (2.7)    2 (2.1)    0.78  
 Distal perfusion catheter, n (%)   45 (61.6)    74 (77.1)    0.029  
Patient already listed before VA-ECMO  
insertion, n (%)     12 (16.4)    35 (36.5)    <0.001  
Time from hospital admission to VA-ECMO  
insertion (days), mean (SD)    7.1 (11.3)    14.8 (24.4)   0.008  
Time from VA-ECMO insertion to high-urgency  
listing (days), mean (SD)    2.8 (2.7)    2.5 (5.7)    0.71  
Ischaemic heart disease, n (%)    45 (61.6)    45 (46.9)    0.057  
Shock secondary to acute myocardial infarction, n (%)  33 (45.2)    21 (21.9)    0.001  
Postcardiotomy shock, n (%)    11 (15.1)    6 (6.2)    0.059  
Cardiopulmonary arrest, n (%)    15 (20.5)    14 (14.6)    0.31  
Previous sternotomy, n (%)    20 (27.4)    25 (26)    0.84  
Diabetes mellitus, n (%)    17 (23.3)    26 (27.1)    0.58  
Peripheral artery disease, n (%)    3 (4.1)    7 (7.3)    0.49  
Chronic obstructive pulmonary disease, n (%)  3 (4.1)    4 (4.2)    0.99  
Active infection requiring i.v. antibiotics, n (%)  7 (9.6)    4 (4.2)    0.16  
INTERMACS profile 1 or 2 (%)   69 (94.5)    86 (89.6)    0.29  
Renal replacement therapy, n (%)   5 (6.8)    7 (7.3)    0.91  
Invasive mechanical ventilation, n (%)   63 (86.3)    68 (70.8)    0.017  
Vasoactive drug support, n (%)    71 (97.3)    81 (85.3)    0.009  
Vasoactive inotropic score (units), mean (SD)  58 (84)    29 (38)    0.012  
Antiplatelet therapy, n (%)        
 Aspirin      19 (26)    32 (33.3)    0.31  
 Clopidogrel     16 (21.9)    9 (9.4)    0.023  
 Other      2 (2.7)    0    0.10  
 Type of antiplatelet therapy      0.008  
  None     50 (68.5)    62 (64.6)    
  One drug     9 (12.3)    27 (28.1)    
  Two drugs     14 (19.2)    7 (7.3)    
Haemoglobin (g/dl), mean (SD)    10 (1.8)    10.8 (2.1)    0.015  
Platelets (103 × µl), mean (SD)    185 (84)    186 (80)    0.91  
INR (UI), mean (SD)    1.38 (0.94)   1.70 (0.96)   0.003  
Creatinine (mg/dl), mean (SD)    1.41 (0.85)   1.37 (0.70)   0.77  
Bilirubin (mg/dl), mean (SD)    1.79 (2.30)   2.02 (2.3)    0.58  
Aspartate lysine aminotransferase (UI/l), mean (SD)  359 (843)    262 (573)    0.43  
Lactate (mmol/l), mean (SD)    2.13 (1.92)   2.60 (2.49)   0.24  
Left ventricular ejection fraction (%), mean (SD)  24 (14)    23 (12)    0.49  
Left ventricular end-diastolic diameter (mm),  
mean (SD)     57 (11)    65 (13)    0.001  
Cardiac index (ml/min/m2), mean (SD)   2.17 (0.77)   1.94 (0.7)    0.20  
Central venous pressure (mmHg), mean (SD)  14 (7)    14 (5)    0.63  
Capillary wedge pressure (mmHg), mean (SD)  22 (8)    24 (3)    0.20  
Mean pulmonary artery pressure (mmHg), mean (SD)  28 (10)    30 (12)    0.089 
IABP: intra-aortic balloon pump; INR: international normalized ratio; INTERMACS: Interagency Registry for Mechanically 





















Fig. 1. Clinical outcomes of VA-ECMO support. P-value for comparison was obtained by means of the χ2 test. IABP: intra-aortic 
balloon pump; VA-ECMO: venoarterial extracorporeal membrane oxygenation. 
Table 2: Cumulative incidence of adverse clinical events during support 
     VA-ECMO + IABP (n = 73) VA-ECMO (n = 96)  P-value 
 
Infection, n (%)     23 (31.5)    29 (30.2)    0.86  
Bleeding event, n (%)    33 (45.2)    24 (25)    0.006  
 Related to vascular access site, n (%)   19 (26)    11 (11.5)    0.014  
 Not related to vascular access site, n (%)   21 (28.8)    14 (14.6)    0.024  
  Thoracic     11 (15.1)    10 (10.4)    0.35  
  Intracranial     3 (4.1)    0    0.045  
  Gastrointestinal     2 (2.7)    0    0.10  
  Urinary tract     1 (1.4)    0    0.25  
  Skin, mucosa and soft tissue   7 (9.6)    3 (3.2)    0.078  
  Other or non-specified    1 (1.4)    2 (2.1)    0.73  
Stroke, n (%)     5 (6.8)    2 (2.1)    0.12  
Device dysfunction, n (%)    5 (6.8)    6 (6.2)    0.88  
Any major clinical adverse eventa, n (%)   45 (61.6)    46 (47.9)    0.076  
Left ventricular dilation syndrome, n (%)   11 (15.1)    14 (14.6)    0.93  
Venous thromboembolism, n (%)   2 (2.7)    4 (4.2)    0.62  
Non-CNS arterial thromboembolism, n (%)  4 (5.5)    6 (6.3)    0.83  
Renal failure requiring dialysis, n (%)   13 (17.8)    15 (15.6)    0.71  
Haemolysis, n (%)     3 (4.1)    6 (6.2)    0.54  
Vascular access site complication, n (%)   20 (27.4)    17 (17.7)    0.13  
Pleural effusion or pneumothorax, n (%)   5 (6.8)    6 (6.2)    0.88  
Pericardial effusion, n (%)    6 (8.2)    3 (3.1)    0.14 
aBleeding, stroke, infection and device dysfunction were considered major clinical adverse events in this study. 
CNS: central nervous system; IABP: intra-aortic balloon pump; VA-ECMO: venoarterial extracorporeal membrane oxygenation. 
Adverse clinical events during venoarterial extracorporeal membrane oxygenation support 
Table 2 shows the cumulative incidence of adverse clinical events during VA-ECMO support. 
Bleeding events were significantly higher among patients in the IABP group compared to the control 
group (45.2% vs 25%, P = 0.006). Significant differences were observed both in the cumulative incidence 
of bleeding events related to vascular access (21.4% vs 11.5%, P = 0.024) and in unrelated events (28.8% 
vs 14.6%, P = 0.024). The cumulative incidence of intracranial bleeding was 4.1% in the intervention 
group and 0% in the control group. By means of logistic regression, the adjusted odds ratio for bleeding 
events in the IABP group versus the control group was 2.18 (95% confidence interval 1.09–4.36; 
P = 0.028; Supplementary Material, Table S1). 
No statistically significant differences were observed between study groups with regard to the 
cumulative incidence of any other adverse clinical events during VA-ECMO support. The left ventricular 
dilation syndrome occurred in 11 patients in the IABP group (15.1%) and 14 patients (14.6%) in the 
control group (P = 0.93). Mechanical strategies for left ventricular unloading in patients who developed 
left ventricular dilation during follow-up included apical venting (n = 2), atrial septostomy (n = 3) and 
percutaneous left ventricular assist device implantation (n = 1). The remaining 19 patients who developed 
this complication were medically managed. 
In-hospital postoperative events after transplantation 
Table 3 shows the cumulative incidence of adverse clinical events during the in-hospital postoperative 
period after HT in 52 (71.2%) patients in the IABP group and 77 (81.2%) patients in the control group 
who were transplanted when under VA-ECMO support. At the time of transplant surgery, the IABP 
remained in place in 45 (86.5%) patients in the IABP group, whereas it had been removed in 7 (13.5%) 
patients. None of the 77 patients in the control group had an IABP implanted during the waiting period 
before transplantation. 
 
In-hospital post-transplant mortality was 34.6% in the IABP group and 32.5% in the control group 
(P = 0.80). We did not find any statistically significant differences between groups with regard to the 
cumulative incidence of other adverse postoperative outcomes or the length of hospital stay, as shown in 
Table 3. 
Table 3: Cumulative incidence of in-hospital postoperative clinical outcomes following heart transplantation 
     VA-ECMO + IABP (n = 52) VA-ECMO alone (n = 77) P-value 
 
Primary graft dysfunction, n (%)   20 (38.5)    22 (28.6)    0.24  
 Right ventricular     6 (11.5)    10 (13)    
 Left ventricular or biventricular   14 (26.9)    12 (15.6)    
Postoperative mechanical circulatory support, n (%)  10 (19.2)    11 (14.3)    0.46  
Excessive surgical bleeding, n (%)   19 (36.5)    20 (26)    0.20  
Redo cardiac surgery, n (%)    9 (17.3)    15 (19.5)    0.76  
Postoperative infection, n (%)    25 (48.1)    41 (53.2)    0.56  
Postoperative renal replacement therapy, n (%)  12 (23.1)    22 (28.6)    0.49  
In-hospital postoperative death, n (%)   18 (34.6)    25 (32.5)    0.80  
Time on ventilator after transplant (days), mean (SD)  11 (14)    12 (24)    0.84  
Time on vasoactive drug support after   
transplant (days), mean (SD)    8 (12)    8 (11)    0.87  
Time in critical care unit after transplant (days), 
 mean (SD)     17 (16)    18 (20)    0.72  
Length of hospital stay after transplant (days),  
mean (SD)     36 (35)    35 (44)    0.82 
IABP: intra-aortic balloon pump; VA-ECMO: venoarterial extracorporeal membrane oxygenation. 
One-year survival after high-urgency listing 
Overall, 79 (46.7%) patients died during the first year after being placed on the high-urgency waiting 
list, with 77 (97.4%) patients occurring before hospital discharge. In-hospital mortality after the high-
urgency listing was 46.6% in the IABP group and 44.8% in the control group (P = 0.82). 
 
According to the Kaplan–Meier method, the estimated 1-year survival probability after the high-
urgency listing was 53.3% in the IABP group and 52.3% in the control group (log rank P = 0.75; Fig. 2). 
 
After adjusting for potential confounders in the multivariable analysis, we observed no statistically 
significant effect of IABP support on the risk of death during the first year after high-urgency listing 







Fig. 2. Cumulative probability of 1-year survival represented by Kaplan–Meier curves. Survival curves were compared by means of 
the log-rank method (P-value is shown in the figure). IABP: intra-aortic balloon pump; VA-ECMO: venoarterial extracorporeal 
membrane oxygenation. 
Impact of centre volume 
The number of patients treated at each one of the participating hospitals is presented in Supplementary 
Material, Fig. S1. Overall, 81 (48%) patients were treated at the 3 centres with the highest volume of 
procedures (institution codes 1, 11 and 16). 
 
The ancillary use of an IABP was associated with no statistically significant impact in 1-year 
cumulative survival, as estimated by the Kaplan–Meier method, either in high-volume centres (IABP: 
60.9% vs Control: 61.2%, P = 0.804), or in low-volume centres (IABP: 50% vs Control: 38.6%, 
P = 0.430). 
Discussion 
In this article, we present a subanalysis of the Spanish multicentre ASIS-TC registry, focused on 
studying the safety and efficacy of the ancillary treatment with an IABP in patients listed for high-
urgency HT under VA-ECMO support. We did not find a significant clinical benefit of the combined 
therapy over VA-ECMO support alone. However, in our series, the combined VA-ECMO plus IABP 
therapy was found to be associated with higher bleeding risk. 
 
 
The prevention and early treatment of left ventricular dilation syndrome is an important goal in 
patients supported with VA-ECMO. This complication, described in up to 20–30% of cases [13], is a 
consequence of increased afterload and may lead to refractory pulmonary congestion and respiratory 
failure, including an increased risk of pulmonary bleeding and infection. To unload the left heart, several 
strategies have been proposed, including percutaneous atrial septostomy [14], insertion of a pigtail 
catheter inside the left ventricle [15], surgical apical venting [16] and simultaneous support with an IABP 
or left ventricular assist devices [17]. 
 
Given its accessibility and easy insertion, IABP is commonly used as an ancillary therapy to unload 
the left ventricle in patients under VA-ECMO support. In patients with left ventricular systolic 
dysfunction, IABP facilitates left ventricular ejection, leading to a moderate increase in cardiac output 
and a substantial reduction in left ventricular end-diastolic pressure and wedge capillary pressure [18, 19], 
so as to prevent pulmonary congestion. A single-centre study [5] involving 259 patients with cardiogenic 
shock who were supported with VA-ECMO showed a significant reduction in radiological signs of 
pulmonary congestion and the duration of mechanical ventilator support among patients who were treated 
simultaneously with an IABP and VA-ECMO compared to patients supported with VA-ECMO alone. 
 
Despite its positive impact on haemodynamics, there is no consistent evidence of a clinical benefit of 
combined therapy with an IABP and VA-ECMO in terms of survival. A pooled analysis of 29 
observational studies, comprising 4576 patients, showed a 10% relative reduction in the risk of in-hospital 
mortality among patients with cardiogenic shock who were treated with VA-ECMO and an IABP when 
compared with those supported solely with VA-ECMO [6]. In addition, a multicentre study based on a 
cohort of 1650 Japanese patients with cardiogenic shock who were supported with VA-ECMO showed a 
26% relative reduction in the risk of death in patients who also were treated with an IABP compared to 
patients supported with VA-ECMO alone [7]. However, a pooled analysis of 16 observational studies 
including 1517 patients did not confirm any clinical benefit of the combined strategy, independent of the 
aetiology of cardiogenic shock or the temporal sequence of insertion of the 2 devices [8]. Finally, a recent 
systematic review of 22 observational studies with 4653 subjects detected a significant impact of 
simultaneous IABP support on survival only in the subgroup of patients supported with VA-ECMO due 
to cardiogenic shock in the setting of acute myocardial infarction, with no effect observed in the whole 
cohort or in patients with other causes of cardiogenic shock [9]. Transplant candidates were minimally 
represented in these studies. Moreover, multicentre series reporting the results of VA-ECMO as a bridge 
to transplantation [10, 11] presented no data regarding the safety and efficacy of simultaneous IABP 
support in this specific setting. 
 
Similar to other studies [7, 9, 20], we were unable to find a significant clinical benefit of simultaneous 
IABP therapy in VA-ECMO-supported candidates for high-urgency HT, neither during the waiting period 
before surgery nor after transplantation. Indeed, combined support was not associated with a significant 
reduction in any of the studied preoperative or postoperative clinical outcomes. 
 
It is notable that there was no significant impact of IABP support on the incidence of left ventricular 
dilation syndrome, which was ∼15% over a mean support duration of 10 days in our cohort. Patients 
receiving concomitant support with VA-ECMO and IABP had left ventricles that were smaller in 
diameter than those of the control group; however, no statistically significant differences regarding mean 
capillary wedge pressures were observed. This finding could be used to argue against the efficiency of 
IABP support to unload the left ventricle; however, this study was not specifically designed to address 
this question, so this finding should be interpreted with caution. Moreover, there was a higher frequency 
of subclavian/axillary artery cannulation in the control group, which might have contributed to a smaller 
increase in left ventricular afterload in these patients [21]. 
 
It should also be noted that patients treated simultaneously with IABP and VA-ECMO in our series 
had a more acute clinical presentation than patients treated with VA-ECMO alone, and a higher 
prevalence of recent myocardial infarction as the cause of shock and a higher requirement for vasoactive 
drugs and invasive mechanical ventilation, indicating a more severe clinical status. Indeed, the majority of 
patients simultaneously treated with both devices at the time of high-urgency listing were already being 
supported with an IABP prior to VA-ECMO implantation. Thus, it is not clear whether asymmetries in 
baseline clinical characteristics between study groups led to confounding bias, even though the observed 
statistical associations showed no substantial variation after comprehensive multivariate adjustment. 
 
One of the most remarkable results of our analysis was the observed independent significant 
association of combined therapy with an increased risk of bleeding events, regardless of whether the 
event was related to the vascular access site. There is no clear explanation for this observation. Previous 
studies have reported increased fibrinolytic activity [22] and a high incidence of thrombocytopaenia [23] 
in patients supported with an IABP; however, the clinical repercussions of these findings remain 
controversial [24]. 
Limitations 
Our study has a few limitations. Firstly, as this study was retrospective, it is at higher risk for potential 
confounding, information and selection biases that are inherent to this type of investigation. Secondly, as 
it included only Spanish candidates for high-urgency HT, the results are not necessarily generalizable to 
other populations. Thirdly, given the study utilized a real-world practice-based registry, the decision and 
timing of IABP implantation were driven by clinical judgement and local protocols rather than by 
predefined criteria. Thus, it is possible that differences in routine clinical practice and experience among 
participating centres might have conditioned the results. Regarding this, we recognize that a mixed effects 
logistic regression analysis (for bleeding events) and a clustered Cox proportional hazards model (for 
survival) might be desirable to control potential centre-related differences in outcomes; however, the 
limited sample size of the study and, more importantly, the small number of patients treated at some of 
the participating hospitals, prevented us from attempting such statistical analyses. 
 
Finally, although we performed a comprehensive multivariate adjustment, we cannot rule out that 
other confounding factors that were not measured in the current study could have affected the observed 
statistical associations. 
Conclusion 
In conclusion, our multicentre, registry-based analysis did not show a significant clinical impact of 
ancillary therapy with an IABP in addition to VA-ECMO support in Spanish candidates for high-urgency 
HT. Larger studies are required to further elucidate the best strategy for left ventricular unloading in 
patients supported with VA-ECMO as a bridge to transplantation. 
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